(202c) Impurity Fate Mapping In the Development of Pazopanib

 Pazopanib hydrochloride is a VEGF antagonist developed by GSK which was approved for the treatment of renal cancer by the FDA and EMEA in 2009 -2010.  Quality by design principles were used in the development of pazopanib hydrochloride.  Impurity fate mapping was used extensively to understand and control impurities.  This paper will discuss the impurity fate mapping strategy for pazopanib hydrochloride and how this strategy helps guarantee patient safety.